Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for sepsis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. Knowledge and understanding of gram-negative sepsis have grown over the past 20 years, but the ability to treat severe sepsis successfully has not.To assess the efficacy and safety of E5 in the treatment of patients with severe gram-negative sepsis.A multicenter, double-blind, randomized, placebo-controlled trial conducted at 136 US medical centers from April 1993 to April (...) 1997, designed with 90% power to detect a 25% relative risk reduction, incorporating 2 planned interim analyses.Intensive care units at university medical centers, Veterans Affairs medical centers, and community hospitals.Adults aged 18 years or older, with signs and symptoms consistent with severe sepsis and documented or probable gram-negative infection.Patients were assigned to receive 2 doses of either E5, a murine monoclonal antibody directed against endotoxin (n = 550; 2 mg/kg per day
Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?
Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?
Intravenous immunoglobulin for treating sepsis and septic shock. Death from severe sepsis and septic shock is common, and researchers have explored whether antibodies to the endotoxins in some bacteria reduces mortality. This review summarises the effects of intravenous immunoglobulin (IVIG) in patients with bacterial sepsis or septic shock on mortality, bacteriological failure rates, and duration of stay in hospital.We searched the Cochrane Controlled Trials Register, Medline 1966 to April (...) 1999, EMBASE 1988 to February 1999; we contacted investigators active in the field for unpublished data.Randomised trials comparing intravenous immunoglobulin (monoclonal or polyclonal) with placebo or no intervention, in patients with bacterial sepsis or septic shock.Inclusion criteria, trial quality assessment, and data abstraction were done in duplicate. We conducted pre-specified subgroup analyses by type of immunoglobulin preparation.Twenty-three out of 49 studies met our inclusion criteria
Vancomycin for prophylaxis against sepsis in preterm neonates. Nosocomial, late onset sepsis occurs in up to 50% of infants of less than 1000gm at birth. The commonest organism isolated is coagulase negative staphylococcus (CoNS). A number of studies have evaluated the efficacy or prophylactic low dose vancomycin given either as a continuous infusion added to the infant's hyperalimentation fluid or by intermittent intravenous administration and these studies in very low birth weight infants (...) are the subject of this review.To evaluate the safety and efficacy of vancomycin prophylaxis for the prevention of late-onset sepsis, coagulase negative staphylococcal sepsis, mortality, and effects on length of stay, total vancomycin exposure, evidence of vancomycin toxicity, and the development of vancomycin resistant organisms in the preterm neonate.Searches were made of Medline, (MeSH terms: Vancomycin and Sepsis; limits: age groups, newborn infants), HealthStar and EMBase, electronic abstracts, personal
Applying epidemiology-based outcomes research to clinical decision-making: a hypothetical model of biotechnology therapy in gram-negative sepsis Applying epidemiology-based outcomes research to clinical decision-making: a hypothetical model of biotechnology therapy in gram-negative sepsis Applying epidemiology-based outcomes research to clinical decision-making: a hypothetical model of biotechnology therapy in gram-negative sepsis Wang E C, Grasela T H, Walawander C A Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Biotechnology therapy in gram-negative sepsis. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The 2 populations studied were patients with nosocomial
Preventing early-onset group B streptococcal sepsis: strategy development using decision analysis Preventing early-onset group B streptococcal sepsis: strategy development using decision analysis Preventing early-onset group B streptococcal sepsis: strategy development using decision analysis Benitz W E, Gould J B, Druzin M L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) of the study Integrated obstetrical and neonatal regimens appropriate to the population served should be adopted by each obstetrical service. Surveillance of costs, complications, and benefits will be essential to guide continued iterative improvement of these strategies. Source of funding Sources of funding were not stated. Bibliographic details Benitz W E, Gould J B, Druzin M L. Preventing early-onset group B streptococcal sepsis: strategy development using decision analysis. Pediatrics 1999; 103(6
Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?
A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic shock PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?
Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Jenson H B, Pollock B H Authors' objectives To determine the effectiveness of intravenous immune globulin (IVIG) in the prevention and treatment of neonatal (...) sepsis. Searching MEDLINE (no dates given) was searched for English language papers plus identification of studies by "personal knowledge". Study selection Study designs of evaluations included in the review Peer-reviewed, prospective randomised trials including a concurrent control group receiving either placebo or no IVIG treatment were eligible for inclusion. IVIG administration had to be given shortly after birth for prophylaxis, or on clinical diagnosis of sepsis for treatment. Specific
Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. To test the effect of a novel bradykinin antagonist, deltibant (CP-0127), on survival, organ dysfunction, and other outcomes in patients with the systemic inflammatory response syndrome (SIRS) and presumed sepsis.Multicenter, randomized, placebo-controlled, double (...) with SIRS and gram-negative sepsis; however, additional studies would be required to prove this.
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. In patients with sepsis the production of arachidonic acid metabolites by cyclooxygenase increases, but the pathophysiologic role of these prostaglandins is unclear. In animal models, inhibition of cyclooxygenase by treatment with ibuprofen before the onset of sepsis reduces physiologic abnormalities and improves survival. In pilot studies of patients with sepsis, treatment (...) with ibuprofen led to improvements in gas exchange and airway mechanics.From October 1989 to March 1995, we conducted a randomized, double-blind, placebo-controlled trial of intravenous ibuprofen (10 mg per kilogram of body weight [maximal dose, 800 mg], given every six hours for eight doses) in 455 patients who had sepsis, defined as fever, tachycardia, tachypnea, and acute failure of at least one organ system.In the ibuprofen group, but not the placebo group, there were significant declines in urinary
p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. To evaluate the safety and efficacy of p55 tumor necrosis factor receptor fusion protein, a recombinant chimeric protein of human p55 (type I) tumor necrosis factor receptor (CD120a) extracellular domain and IgG1 sequences (referred to as p55-IgG), in the treatment of patients with severe sepsis or septic (...) shock.Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial.Forty-four community and university-affiliated hospitals in the United States and Europe.There were 498 patients enrolled in this clinical trial.Patients prospectively stratified within each site into refractory shock or severe sepsis groups were randomized to receive a single infusion of p55-IgG, 0.083 mg/kg, 0.042 mg/kg, or 0.008 mg/kg, or placebo. Patients received standard aggressive medical/surgical care during
Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Trotter C W Authors' objectives To evaluate methods of reducing catheter-related sepsis (CRS) in high-risk neonates. Searching MEDLINE, CINAHL (...) on the methods of this review. Literature searches were performed from 1990 onwards as the author states that she had previously reviewed literature published prior to 1990; however, no reference for this is provided. Implications of the review for practice and research There is a need for randomised controlled trials of methods to reduce CRS. Bibliographic details Trotter C W. Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994. Neonatal
Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. Patients with acute respiratory distress syndrome (ARDS) have a deficiency of surfactant. Surfactant replacement improves physiologic function in such patients, and preliminary data suggest that it may improve survival.We conducted a prospective, multicenter, double-blind, randomized, placebo-controlled trial involving 725 patients with sepsis (...) analyzed according to APACHE III score, cause of death, time of onset and severity of ARDS, presence or absence of documented sepsis, underlying disease, whether or not there was a do-not-resuscitate order, and medical center. Increased secretions were significantly more frequent in the surfactant group; the rates of other complications were similar in the two groups.The continuous administration of aerosolized synthetic surfactant to patients with sepsis-induced ARDS had no significant effect on 30
Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: a prospective randomized multicenter study. To evaluate the effect of catheter tunneling on internal jugular catheter-related sepsis in critically ill patients.A prospective randomized controlled study involving 3 intensive care units (ICUs), stratified by number of catheter lumina (1 or 2) and center.The 10-bed medical-surgical and 10-bed surgical ICUs at Saint Joseph Hospital and 8-bed (...) surgical ICU at Clinique de la Défense, Paris, France.Every patient older than 18 years admitted to the ICUs between March 1, 1993, and July 17,1996, who required a jugular venous catheter for more than 48 hours.Random allocation to tunneled or nontunneled catheters.Times to occurrence of systemic catheter-related sepsis, catheter-related septicemia, or a quantitative catheter-tip culture with a cutoff of 103 colony-forming units per milliliter.A total of 241 patients were randomized. Ten patients
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. A recombinant, soluble fusion protein that is a dimer of an extracellular portion of the human tumor necrosis factor (TNF) receptor and the Fc portion of IgG1 (TNFR:Fc) binds and neutralizes TNF-alpha and prevents death in animal models of bacteremia and endotoxemia.To evaluate the safety and efficacy of TNFR:Fc in the treatment of septic shock, we conducted